Multiple preclinical studies have confirmed that the combination of PARP and PI3K/AKT pathway inhibitors has synergistic antitumor activity in breast cancer susceptibility gene (BRCA)-deficient cancer models [112]. This evidence concerns the gene PIK3CA and cancer.